Drug Approval | February 24, 2024
Orchid Pharma's 'Exblifep' receives USFDA approval
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
_256_384.jpg)
The Vice President also highlighted the importance of preventive healthcare and fitness
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
These digital avenues have not only revolutionized patient care but also opened up new opportunities for HCPs to build thought leadership in their respective fields
The fast pace of construction of AIIMS Jammu whose foundation stone laying to inauguration took only 5 years highlights the commitment of the Government
The preventive and promotive approach of our traditional health care systems has played a significant role in modern age today
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
Subscribe To Our Newsletter & Stay Updated
